Study guide
NMOSD and MOGAD
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
NMOSD and MOGAD
Key Takeaways Explain This Topic AI
AQP4-associated NMOSD is an astrocytopathy distinct from typical MS-related optic neuritis.
MOGAD can have bilateral or recurrent optic involvement and requires a compatible phenotype and antibody interpretation.
Acute treatment, taper and relapse prevention need individualized specialist planning rather than one fixed course for all atypical neuritis.
Last updated: October 2026
Atypical Optic Neuritis: NMOSD & MOGAD
Atypical features that deviate from typical MS-associated optic neuritis mandate an immediate search for non-MS autoimmune demyelinating conditions. Red flag warning signs include:
- Bilateral simultaneous or rapidly sequential vision loss
- Severe, catastrophic visual acuity impairment (e.g., light perception or no light perception)
- Absence of eye movement-induced pain
- Lack of visual improvement within 3 to 4 weeks of symptom onset
- Marked anterior disc swelling with extensive retinal haemorrhages or macular exudates
- Associated severe myelopathic or intractable systemic signs
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Pathophysiology & Biomarkers
NMOSD is a severe, relapsing, antibody-mediated autoimmune astrocytopathy with secondary demyelination and axonal injury. Aquaporin-4 antibodies (AQP4-IgG / NMO-IgG) identify the characteristic antibody-positive form; antibody-negative NMOSD requires stricter clinical and MRI criteria, with exclusion of alternative diagnoses. Aquaporin-4 is a bidirectional water channel highly concentrated on the foot processes of astrocytes that abut blood vessels at the blood-brain barrier and ependymal surfaces. Binding of AQP4-IgG triggers classical complement activation (membrane attack complex deposition), granulocyte and macrophage infiltration, astrocytic foot process necrosis, and secondary bystander demyelination with irreversible axonal transection.
Clinical Presentation & Distinctive Syndromes
NMOSD is characterised by a strong female preponderance (up to 9:1) and a slightly older age of onset (median 35-45 years), with increased incidence in individuals of African, Asian, and Latin American ancestry:
Severe, Bilateral or Sequential Optic Neuritis: Visual loss is catastrophic; up to 50% of affected eyes deteriorate to counting fingers or worse. Spontaneous visual recovery is notoriously poor without aggressive acute rescue therapy.
Posterior Optic Nerve & Chiasmal Involvement: MRI typically reveals longitudinally extensive gadolinium enhancement of the optic nerve, frequently involving the intracranial segment and extending across the optic chiasm , producing bitemporal hemianopic field defects .
Longitudinally Extensive Transverse Myelitis (LETM): Contiguous spinal cord lesions spanning ≥ 3 \ge 3 ≥ 3 complete vertebral segments on sagittal T2-weighted MRI, presenting with severe paraplegia, sensory loss, and neurogenic bladder/bowel dysfunction.
Area Postrema Syndrome: Intractable, unexplained nausea, vomiting, or persistent hiccups lasting ≥ 48 \ge 48 ≥ 48 hours, caused by inflammation of the medullary area postrema (a circumventricular organ rich in AQP4 lacking a tight blood-brain barrier).
Treatment Protocols in NMOSD
Acute relapse : Treat urgently with specialist high-dose corticosteroids and consider early plasma exchange for severe disease or inadequate response; do not wait for an arbitrary deadline.
Maintenance Immunotherapy: AQP4-positive NMOSD can cause severe recurrent attacks, and specialist preventive therapy is usually needed. The choice depends on antibody status, relapse course, comorbidity, infection precautions and local approval; do not infer that every attack is incapable of spontaneous improvement or apply one mandatory regimen to all seronegative optic neuritis:
- B-cell depletion: Rituximab (anti-CD20) or Inebilizumab (anti-CD19)
- Complement inhibition: Eculizumab or Ravulizumab (anti-C5 terminal complement inhibitor)
- Interleukin-6 receptor blockade: Satralizumab or Tocilizumab
Caution
Conventional Multiple Sclerosis disease-modifying therapies—specifically interferon-beta, fingolimod, natalizumab, and alemtuzumab —are ineffective in NMOSD and can precipitate fulminant, catastrophic, life-threatening disease exacerbations.
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
- Pathophysiology & Biomarkers
MOGAD is a distinct inflammatory demyelinating disorder mediated by IgG autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG) . MOG is a transmembrane protein expressed on the outermost lamellae of the myelin sheath and oligodendrocyte plasma membranes. In contrast to NMOSD, MOGAD is a primary demyelinating condition rather than an astrocytopathy, resulting in less tissue necrosis and substantial potential for remyelination.
Clinical Presentation & Distinctive Syndromes
Demographics: Occurs in both children and adults, with an equal male-to-female ratio (1:1 to 1.5:1).
Prominent Papillitis (Optic Disc Oedema): In contrast to typical MS-ON (where 65% is retrobulbar), optic disc swelling is present in > 80 % >80\% > 80% of MOGAD-ON cases. The disc swelling is frequently severe, accompanied by hyperaemia, splinter haemorrhages, and peripapillary subretinal fluid.
Bilateral Simultaneous Optic Neuritis: Seen in up to 50% of presentations, accompanied by severe retro-orbital pain.
Optic Perineuritis on MRI: Orbital MRI characteristically reveals longitudinally extensive enhancement of the optic nerve sheath and adjacent intraorbital fat ( optic perineuritis ) with sparing of the optic chiasm and brain parenchyma.
Visual Recovery vs. Steroid Dependence: Initial visual loss is often profound (nadir < 20 / 200 <20/200 < 20/200 ), but exhibits exquisite, rapid responsiveness to corticosteroid therapy . However, MOGAD demonstrates a notorious tendency for steroid-dependent relapse when oral prednisone is tapered rapidly or withdrawn within weeks.
Treatment Protocols in MOGAD
Acute Therapy: High-dose IV methylprednisolone (1,000 mg/day for 3 to 5 days).
Taper and prevention : Plan specialist taper and relapse prevention according to MOGAD course and toxicity; do not impose a mandatory 3–6-month minimum on every patient.
Diagnostic Comparison: MS-ON vs. NMOSD vs. MOGAD
The following table summarizes the differential diagnostic features essential for the EBOD examination:
Clinical & Diagnostic Domain Typical MS-Associated ON NMOSD-Associated ON MOGAD-Associated ON
Primary Biomarker Negative for AQP4 and MOG; CSF oligoclonal bands (OCBs) present in > 90 % >90\% > 90% Serum AQP4-IgG (cell-based assay; sensitivity 75-80%) Serum MOG-IgG (cell-based assay; high titers)
Underlying Pathophysiology Autoimmune CD4+ T-cell mediated demyelination Autoimmune astrocytopathy with complement-mediated necrosis Autoimmune demyelination of outermost myelin sheaths
Demographics Females 20-40 years (F:M ratio ~3:1) Females 30-50 years (F:M ratio up to 9:1; non-Caucasian) Children and young adults (F:M ratio ~1:1 to 1.5:1)
Laterality & Presentation Unilateral (>95%); subacute onset Unilateral or bilateral sequential/simultaneous; severe Bilateral simultaneous (up to 50%) or unilateral
Orbital Pain Present in 92%; exacerbated by eye movements Variable; may be present or absent Severe in > 85 % >85\% > 85% ; retro-orbital and movement-induced
Optic Disc Appearance Retrobulbar in 65%; mild papillitis in 35% Normal or moderate swelling; early optic atrophy Marked papillitis in > 80 % >80\% > 80% ; peripapillary haemorrhages
Visual Nadir & Recovery Moderate nadir; > 90 % >90\% > 90% recover to ≥ 20 / 40 \ge 20/40 ≥ 20/40 spontaneously Catastrophic nadir ; poor recovery without PLEX Severe nadir; rapid and dramatic steroid recovery
Orbital MRI Findings Focal, short-segment enhancement ( < 1 cm <1\text{ cm} < 1 cm ), anterior Long-segment enhancement extending to optic chiasm Long-segment enhancement with perineuritis (sheath/fat)
Brain / Spine MRI Periventricular Dawson's fingers; short spinal cord lesions Normal brain or periependymal lesions; LETM ( ≥ 3 \ge 3 ≥ 3 segments) Normal or large, fluffy, hazy cortical/subcortical lesions
Acute Management IV methylprednisolone 1 g/day (3 days); NO oral alone IV methylprednisolone 1 g/day (5 days) + early PLEX IV methylprednisolone 1 g/day + slow oral taper (3-6 mo)
Maintenance Therapy MS disease-modifying therapies (DMTs) Rituximab, eculizumab, satralizumab, inebilizumab IVIG, mycophenolate, rituximab (if relapsing)
Applying Historical ONTT Results Today
ONTT found increased recurrence with oral prednisone 1 mg/kg/day alone; this is a specific low-dose regimen, not a prohibition on all oral corticosteroid treatment. Bioequivalent high-dose oral regimens can be used in selected adults under specialist protocols. Typical optic neuritis often recovers, while corticosteroids mainly accelerate recovery. MRI findings and clinical features inform longer-term neurological assessment rather than a single white-matter lesion automatically establishing MS.
The 2024 McDonald revisions, published in 2025, allow the optic nerve as a fifth dissemination-in-space location when appropriately demonstrated and no better explanation exists. Diagnosis still requires the complete neurological criteria. See the revised criteria . Test AQP4/MOG antibodies when the phenotype supports these conditions and interpret assay quality and pretest probability; indiscriminate testing can yield misleading positives. Seronegative NMOSD requires its own stricter clinical/imaging criteria.
Severe atypical disease needs urgent specialist treatment. Plasma exchange may be started early for inadequate response rather than waiting a fixed five-to-seven-day deadline. MOGAD relapse risk and steroid taper are individualised; every patient does not require a mandatory three-to-six-month course. NMOSD preventive drugs depend on antibody status, jurisdiction and infection/vaccination precautions, including meningococcal protection for complement inhibitors.